ArticleJapanese journal of radiology2026
Global research landscape of PSMA-targeted radiopharmaceuticals: a two-decade multidimensional bibliometric analysis.
Article in Japanese journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting perivascular adipose tissue in vascular aging: innovative translational strategies for disease prevention and monitoring.Apoptosis : an international journal on programmed cell death · 2026Review
- A bibliometric analysis of the role of apoptosis in breast cancer immunotherapy from 1994 to 2024.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aims to conduct a comprehensive bibliometric analysis of global research in prostate-specific-membrane-antigen (PSMA)-targeted radiopharmaceuticals to map the field's development, identify key contributors, and determine emerging research directions. PSMA-targeted radiopharmaceuticals have revolutionized prostate cancer theranostics, yet comprehensive bibliometric analyses examining the global research landscape remain absent. Understanding research trends, collaborative networks, and emerging directions is crucial for optimizing resource allocation and guiding future development in this rapidly evolving field. MATERIALS AND
methodsThis study examined 3,249 publications related to PSMA-targeted radiopharmaceuticals from 2005 to 2025 using the Web of Science Core Collection database. Data visualization and analysis were conducted using VOSviewer (version 1.6.19), CiteSpace (version 6.2.R3), and the biblioshiny R package.
resultsThe analysis included 77 countries, 3,350 institutions, and 13,976 researchers across 430 journals. Germany leads with 869 publications and 40,615 citations, with Technical University Munich identified as the most influential institution (n = 199). The European Journal of Nuclear Medicine and Molecular Imaging has the highest number of publications (n = 316), while Journal of Nuclear Medicine has the most co-citations (14,245). Matthias Eiber is the most prolific author with 153 publications and an H-index of 57, while A. Afshar-Oromieh has the highest number of co-citations (n = 2248). The citation patterns showed strong growth after 2018 (surpassing 14,000 citations by 2024), reflecting the field's impact. The current research hotspots mainly include "
conclusionsThis analysis describes the evolution of PSMA radiopharmaceuticals research patterns and identifies emerging research directions that may inform future precision oncology development.
Indexed as
Identifiers
41068527What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.